Beta radioligand → alpha radioligand
After lutetium therapy stops working, an actinium version of the same drug can still produce responses.
225Ac-PSMA-617 after 177Lu-PSMA failure: PSA responses in ~50-60% in retrospective series; phase 3 trials (AcTION, AlphaBreak) ongoing; RYZ101 ACTION-1 in post-Lutathera NETs.
Pages like this
not linked directly; found by shared links- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
Shares Actinium-225 PSMA agents, Alpha vs beta emitters, Lutetium-177 vipivotide tetraxetan, Targeted alpha therapy.
- CompanyRayzeBio (BMS)
Shares Actinium-225 DOTATATE, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Neuroendocrine tumours.
- InstitutionChulabhorn Hospital / Chulabhorn Royal Academy
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Targeted alpha therapy, Neuroendocrine tumours.
- TrialACTION-1
Shares Actinium-225 DOTATATE, Lutetium-177 dotatate, Targeted alpha therapy, Neuroendocrine tumours.
- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
Shares Actinium-225 DOTATATE, Actinium-225 PSMA agents, Targeted alpha therapy, Radioligand therapy (beta emitters).
- CompanyFusion Pharmaceuticals (AstraZeneca)
Shares Actinium-225 PSMA agents, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- InstitutionPostgraduate Institute of Medical Education and Research, Chandigarh
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PairingBeta PRRT → alpha PRRT
Shares Alpha vs beta emitters, Lutetium-177 dotatate, Targeted alpha therapy, Neuroendocrine tumours.